The firm said the clinical trial pause is temporary as an independent data monitoring committee finalizes its analysis for submission to regulators.
U.S. IND clearance follows recent approval of CTA for EPI-321 in facioscapulohumeral muscular dystrophy (FSHD) in New Zealand ...
Hemogenyx Pharmaceuticals Files Annual IND Report with FDA for HG-CT-1 CAR-T Therapy for AML LONDON, UK / ACCESS Newswire / April 3, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) is pleased to annou ...
Toxicity related to the systematic delivery of IL-12, a well-known and widely researched anti-tumor cytokine, has limited its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback